Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne.
Diane M ThiboutotNoah CraftRobert RissmannEwa GatlikMalika SouquièresJulie JonesChristian LoeschePublished in: The Journal of dermatological treatment (2022)
Anti-IL-17A therapy was not significantly different compared to the placebo in reducing inflammatory lesions in patients with moderate to severe acne.